A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
Completed
Takeda
Phase 3
2016-03-26
The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in
patients having pain symptoms associated with uterine fibroids.
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
Completed
Takeda
Phase 3
2016-03-05
The purpose of this study is to evaluate the efficacy of Relugolix (TAK-385) 40 mg
administered orally once daily for 12 weeks, compared with leuprorelin injection (once every
4 weeks, 1.88 mg or 3.75 mg subcutaneously [SC]/time) in patients with uterine fibroids.
LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Completed
Myovant Sciences GmbH
Phase 3
2017-04-26
The purpose of this study is to determine the benefit of relugolix 40 milligrams (mg) once a
day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared
with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
